The authors identified and clinically validated the small‐molecule compound Tubuloside A as a potential therapeutic agent targeting ABCF1‐K430la for the treatment of HCC tumours124 (Table 2). This evidence concerns the gene ABCF1 and hepatocellular carcinoma.